Cerebral Protection Device Aids Patients Undergoing TAVI

This article originally appeared here.
Share this content:
Cerebral Protection Device Aids Patients Undergoing TAVI
Cerebral Protection Device Aids Patients Undergoing TAVI

WEDNESDAY, Aug. 10, 2016 (HealthDay News) -- For patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI), use of a cerebral protection device is associated with a reduction in the frequency of ischemic cerebral lesions, according to a study published in the Aug. 9 issue of the Journal of the American Medical Association.

Stephan Haussig, M.D., from the University of Leipzig in Germany, and colleagues examined the effect of a cerebral protection device on the number and volume of cerebral lesions in patients undergoing TAVI in a single-center randomized trial. Patients with severe aortic stenosis undergoing TAVI underwent brain magnetic resonance imaging at baseline and two and seven days after TAVI. One hundred patients were randomized in a 1:1 ratio to TAVI with a cerebral protection device (filter group) or without a cerebral protection device (control).

The researchers found that the primary end point of the number of new lesions was lower in the filter versus the control group (4.00 versus 10.00; P < 0.001). There was a lower new lesion volume after TAVI in the filter group compared to the control group (527 versus 242 mm³; P = 0.001).

"Larger studies are needed to assess the effect of cerebral protection device use on neurological and cognitive function after TAVI and to devise methods that will provide more complete coverage of the brain to prevent new lesions," the authors write.

Several authors disclosed financial ties to pharmaceutical and medical device companies, including Claret Medical and Medtronic, which funded the study.

Abstract
Full Text
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »